BC is a highly heterogeneous disease, classified into distinct molecular subtypes based on the expression of classic biomarkers such as estrogen receptors (ERs), progesterone receptors (PRs), and Human Epidermal Growth Factor Receptor 2 (HER2) [4]. This evidence concerns the gene PGR and breast cancer.